Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "''NCCN does not have guidelines" to "''NCCN does not currently have guidelines") |
||
Line 19: | Line 19: | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
− | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf NCCN Guidelines - Central Nervous System Cancers].'' | + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf NCCN Guidelines - Central Nervous System Cancers].'' |
[[Category:Meningioma regimens]] | [[Category:Meningioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] |
Revision as of 19:59, 29 November 2023
Section editor | |
---|---|
Seema Nagpal, MD Stanford University Palo Alto, CA, USA |
Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
0 regimens on this page
0 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
EANO
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.